Avosentan reduces albumin excretion in diabetics with macroalbuminuria.

No abstract is available for this paper.

• Publication year

  2009

• Venue

  Journal of the American Society of Nephrology

• Publication date

  2009-03-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1681/ASN.2008050482PMID 19144760PMCID PMC2653691
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Renal Protection in Hypertensive Patients: Selection of Antihypertensive Therapy

  2012cited by this paper
• Aliskiren combined with losartan in type 2 diabetes and nephropathy.

  2008cited by this paper
• Endothelin A receptor blockade reduces diabetic renal injury via an anti-inflammatory mechanism.

  2007cited by this paper
• KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Diabetes and Chronic Kidney Disease.

  2007cited by this paper
• Role of endothelin and endothelin receptor antagonists in renal disease

  2006cited by this paper
• Role of Angiotensin-1-Receptor Blockers In Cardiorenal Disease

  2006cited by this paper
• Effects of long-term fenofibrate therapy on cardiovascular events in 9795 people with type 2 diabetes mellitus (the FIELD study): randomised controlled trial.

  2005cited by this paper
• Effect of sodium intake on blood pressure and albuminuria in Type 2 diabetic patients: the role of insulin resistance

  2004cited by this paper
• THE ETA-SELECTIVE ANTAGONIST SPP301 REDUCES PROTEINURIA IN PATIENTS WITH DIABETIC NEPHROPATHY ON TOP OF HIGH-DOSE AT1 RECEPTOR BLOCKADE (ARB): P3.256

  2004cited by this paper
• Pharmacokinetics and Pharmacodynamics of the ETA‐Selective Endothelin Receptor Antagonist SPP301 in Healthy Human Subjects

  2004cited by this paper
• Albuminuria, a Therapeutic Target for Cardiovascular Protection in Type 2 Diabetic Patients With Nephropathy

  2004cited by this paper
• Physiology and pathology of endothelin-1 in renal mesangium.

  2003cited by this paper
• Nephroprotective Effect of Bosentan in Diabetic Rats

  2003cited by this paper
• The Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure: the JNC 7 report.

  2003cited by this paper
• Seventh report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure.

  2003cited by this paper
• The risk of developing end-stage renal disease in patients with type 2 diabetes and nephropathy: the RENAAL study.

  2003cited by this paper
• A controlled, prospective study of the effects of atorvastatin on proteinuria and progression of kidney disease.

  2003cited by this paper
• Development and progression of nephropathy in type 2 diabetes: the United Kingdom Prospective Diabetes Study (UKPDS 64).

  2003cited by this paper
• Microalbuminuria Reduction With Valsartan in Patients With Type 2 Diabetes Mellitus: A Blood Pressure–Independent Effect

  2002cited by this paper
• The effect of irbesartan on the development of diabetic nephropathy in patients with type 2 diabetes.

  2001cited by this paper
• Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes.

  2001cited by this paper
• Blood pressure-independent additive effects of pharmacologic blockade of the renin-angiotensin and endothelin systems on progression in a low-renin model of renal damage.

  2001cited by this paper
• Endothelin antagonists in the treatment of renal failure.

  2001cited by this paper
• Effects of Endothelin Receptor Antagonists on the Progression of Diabetic Nephropathy

  2001cited by this paper
• Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy.

  2001cited by this paper
• Hyperhexosemia Induced Functional and Structural Changes in the Kidneys: Role of Endothelins

  2001cited by this paper
• The role of ACE inhibitors and angiotensin II receptor blockers in the response to epoetin.

  1999cited by this paper
• Endothelin in cardiovascular control: The role of endothelin antagonists

  1999cited by this paper
• Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33). UK Prospective Diabetes Study (UKPDS) Group.

  1998cited by this paper
• Urinary endothelin in adolescents and young adults with insulin-dependent diabetes mellitus: relation to urinary albumin, blood pressure, and other factors.

  1998cited by this paper
• Unselective inhibition of endothelin receptors reduces renal dysfunction in experimental diabetes.

  1998cited by this paper
• Circulating endothelin-1 in non-insulin-dependent diabetic patients with retinopathy.

  1997cited by this paper
• Effects of Sodium Intake on Albumin Excretion in Patients with Diabetic Nephropathy Treated with Long-Acting Calcium Antagonists

  1996cited by this paper
• Salt intake and reductions in arterial pressure and proteinuria. Is there a direct link?

  1996cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1994cited by this paper
• Endothelins: molecular biology, biochemistry, pharmacology, physiology, and pathophysiology.

  1994cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy. The Collaborative Study Group.

  1993cited by this paper
• The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy.

  1993cited by this paper
• Metabolic effects of converting enzyme inhibitors: focus on the reduction of cholesterol and lipoprotein(a) by fosinopril.

  1993cited by this paper
• [Results of multicenter determination of preliminary reference values for albumin in urine of children and adults].

  1991cited by this paper
• Intravenously administered frusemide increases glomerular permeability.

  1987cited by this paper
• Urinary protein as measured with a pyrogallol red-molybdate complex, manually and in a Hitachi 726 automated analyzer.

  1986cited by this paper

• Meta-Analysis of Randomized Controlled Trials Assessing the Efficacy and Safety of Endothelin Receptor Antagonists in Chronic Kidney Disease.

  2026cites this paper
• Endothelin-1 and cardio-kidney events among patients with CKD, diabetes, and anemia.

  2025cites this paper
• Opportunities and challenges in the treatment of IgA nephropathy

  2025cites this paper
• Potential New Treatments for Chronic Kidney Diseases: A Concise Review.

  2025cites this paper
• NETosis in diabetic kidney disease: Molecular mechanisms and therapeutic opportunities.

  2025cites this paper
• Research trends and performance of endothelin A receptor antagonist in kidney care: a bibliometric analysis

  2025cites this paper
• Selective endothelin A receptor antagonism in chronic kidney disease: improving clinical application

  2025cites this paper
• Endothelial Vasoactive Pathways and Renal Outcomes: A Drug-Target Mendelian Randomization and Transcriptome-Wide Association Study

  2025cites this paper
• CKDs at the Crossroads: From Failures to Future Therapies

  2025cites this paper
• Endothelin receptor antagonists for diabetic kidney disease: back to the future?

  2025cites this paper
• Sparsentan: Sparsentan- A novel, non- immunosuppressive, dual action angiotensin II and endothelin A receptor antagonist -A new hope for glomerular disease

  2024cites this paper
• Proteinuria and Progression of Renal Damage: The Main Pathogenetic Mechanisms and Pharmacological Approach

  2024cites this paper
• Endothelin Inhibitors in Chronic Kidney Disease: New Treatment Prospects

  2024cites this paper
• Advancements in Diabetic Kidney Disease Management: Integrating Innovative Therapies and Targeted Drug Development.

  2024cites this paper
• SGLT2i and GLP1-RA exert additive cardiorenal protection with a RAS blocker in uninephrectomized db/db mice

  2024cites this paper
• Endothelin receptor antagonists in chronic kidney disease

  2024cites this paper
• Mechanism of protective actions of sparsentan in the kidney: lessons from studies in models of chronic kidney disease

  2024cites this paper
• Post-hoc analysis of the SONAR trial indicates that the endothelin receptor antagonist atrasentan is associated with less pain in patients with type 2 diabetes and chronic kidney disease.

  2023cites this paper
• Pathomechanisms of Diabetic Kidney Disease

  2023cites this paper
• Endothelin Receptor Antagonists in Kidney Disease

  2023cites this paper
• Fluid retention and heart failure in the PRECISION trial.

  2023cites this paper
• Efficacy and safety of zibotentan and dapagliflozin in patients with chronic kidney disease: study design and baseline characteristics of the ZENITH-CKD trial

  2023cites this paper
• Taming resistant hypertension: The promise of novel pharmacologic approaches and renal denervation

  2023cites this paper
• Endothelin receptor antagonists in kidney protection for diabetic kidney disease and beyond?

  2022cites this paper
• Increase in BNP in Response to Endothelin-Receptor Antagonist Atrasentan Is Associated With Incident Heart Failure.

  2022cites this paper
• Endothelin Receptor Antagonists for Kidney Protection.

  2022cites this paper
• Advances in the management of diabetic kidney disease: beyond sodium-glucose co-transporter 2 inhibitors

  2022cites this paper
• Lack of renoprotective effects of targeting the endothelin A receptor and/or sodium glucose transporter 2 in a mouse model of type 2 diabetic kidney disease.

  2022cites this paper
• Exploring the pivotal role of endothelin in rheumatoid arthritis

  2022cites this paper
• Expectations in children with glomerular diseases from SGLT2 inhibitors

  2022cites this paper
• Dual endothelin antagonist aprocitentan for resistant hypertension (PRECISION): a multicentre, blinded, randomised, parallel-group, phase 3 trial.

  2022cites this paper
• A Strategic Investigation on Diabetic Nephropathy; Its Conceptual Model and clinical Manifestations: A Review.

  2022cites this paper
• IgA nephropathy: an overview of drug treatments in clinical trials

  2022cites this paper
• Enhanced Cardiorenal Protective Effects of Combining SGLT2 Inhibition, Endothelin Receptor Antagonism and RAS Blockade in Type 2 Diabetic Mice

  2022cites this paper
• Empagliflozin Inhibits IL-1β-Mediated Inflammatory Response in Human Proximal Tubular Cells

  2021cites this paper
• Diabetic nephropathy: A twisted thread to unravel.

  2021cites this paper
• Uric acid as a cardiorenal mediator: pathogenesis and mechanistic insights

  2021cites this paper
• Therapeutic and delivery strategies of phytoconstituents for renal fibrosis.

  2021cites this paper
• Cardiometabolic and Kidney Protection in Kidney Transplant Recipients With Diabetes: Mechanisms, Clinical Applications, and Summary of Clinical Trials

  2021cites this paper
• Endothelin‐1 levels are decreased in pediatric Type 1 diabetes and negatively correlate with the carotid intima media thickness

  2021cites this paper
• Design of FLAIR: a Phase 2b Study of the 5-Lipoxygenase Activating Protein Inhibitor AZD5718 in Patients With Proteinuric CKD

  2021cites this paper
• Update on diagnosis, pathophysiology, and management of diabetic kidney disease

  2021cites this paper
• Endothelin Receptor Antagonists as a Potential Treatment of Diabetic Nephropathy: A Systematic Review

  2021influential citation
• Endothelin receptor antagonists for the treatment of diabetic and nondiabetic chronic kidney disease

  2021influential citation
• Efficacy and safety of endothelin receptor antagonists in type 2 diabetic kidney disease: A systematic review and meta‐analysis of randomized controlled trials

  2020cites this paper
• Empagliflozin Inhibits Basal and IL-1β-Mediated MCP-1/CCL2 and Endothelin-1 Expression in Human Proximal Tubular Cells

  2020cites this paper
• Endothelin-targeted new treatments for proteinuric and inflammatory glomerular diseases: focus on the added value to anti-renin-angiotensin system inhibition

  2020cites this paper
• Beneficial effect on podocyte number in experimental diabetic nephropathy resulting from combined Atrasentan and RAAS inhibition therapy.

  2020cites this paper
• The endothelin system as target for therapeutic interventions in cardiovascular and renal disease.

  2020cites this paper
• The new biology of diabetic kidney disease - mechanisms and therapeutic implications.

  2020cites this paper
• Selective endothelin A receptor antagonism in patients with proteinuric chronic kidney disease

  2020cites this paper
• Pathophysiology of Proteinuria: Albuminuria as a Target for Treatment

  2020cites this paper
• Approach to the Patient with Non-nephrotic Proteinuria

  2020cites this paper
• Endothelin receptor antagonists for the treatment of diabetic nephropathy: A meta-analysis and systematic review

  2020cites this paper
• Exosomal circ_DLGAP4 promotes diabetic kidney disease progression by sponging miR-143 and targeting ERBB3/NF-κB/MMP-2 axis

  2020cites this paper
• Novel strategies of hypertension management in chronic kidney disease

  2020cites this paper
• New pharmacological strategies for protecting kidney function in type 2 diabetes.

  2019cites this paper
• Endothelin Receptor Antagonism Improves Lipid Profiles and Lowers PCSK9 (Proprotein Convertase Subtilisin/Kexin Type 9) in Patients With Chronic Kidney Disease

  2019influential citation
• New Therapies for the Treatment of Renal Fibrosis.

  2019cites this paper
• Atrasentan and renal events in patients with type 2 diabetes and chronic kidney disease (SONAR): a double-blind, randomised, placebo-controlled trial.

  2019cites this paper
• Endothelin: 30 Years From Discovery to Therapy.

  2019cites this paper
• Endothelins in cardiovascular biology and therapeutics

  2019cites this paper
• Diabetes mellitus Typ 2: Wie schützen wir die Nieren am besten?

  2019cites this paper
• Sustained, delayed, and small increments in glomerular permeability to macromolecules during systemic ET-1 infusion mediated via the ETA receptor.

  2019cites this paper
• Therapy of scleroderma renal crisis: State of the art.

  2018cites this paper
• (Clinical) Trial and Error in Diabetic Nephropathy

  2018cites this paper
• Deleting Death and Dialysis: Conservative Care of Cardio-Vascular Risk and Kidney Function Loss in Chronic Kidney Disease (CKD)

  2018cites this paper
• Rationale and protocol of the Study Of diabetic Nephropathy with AtRasentan (SONAR) trial: A clinical trial design novel to diabetic nephropathy

  2018cites this paper
• Canagliflozin and renal outcomes in type 2 diabetes: results from the CANVAS Program randomised clinical trials.

  2018cites this paper
• Antiproteinuric effect of an endothelin-1 receptor antagonist in puromycin aminonucleoside-induced nephrosis in rat

  2018cites this paper
• Anti-fibrotic treatments: A review of clinical evidence.

  2018cites this paper
• Defining the Optimal Dose of Atrasentan by Evaluating the Exposure-Response Relationships of Albuminuria and Bodyweight

  2018cites this paper
• Determining the optimal dose of atrasentan by evaluating the exposure‐response relationships of albuminuria and bodyweight

  2018cites this paper
• Translational science in albuminuria: a new view of de novo albuminuria under chronic RAS suppression.

  2018cites this paper
• Update on Endothelin Receptor Antagonists in Hypertension

  2018cites this paper
• Treatment of Diabetic Kidney Disease With Hypertension Control and Renin Angiotensin System Inhibition.

  2018cites this paper
• University of Groningen Determining the optimal dose of atrasentan by evaluating the exposure-response relationships of albuminuria and bodyweight Koomen,

  2018cites this paper
• Novel therapies for diabetic kidney disease.

  2018cites this paper
• Reversibility of Renal Fibrosis

  2017cites this paper
• Association of oral endothelin receptor antagonists with risks of cardiovascular events and mortality: meta-analysis of randomized controlled trials

  2017cites this paper
• Endothelin-receptor antagonist can reduce blood pressure in patients with hypertension: a meta-analysis

  2017influential citation
• Treatment of Hypertension in Light of the New Guidelines: Pharmacologic Approaches Using Combination Therapies

  2017cites this paper
• Long-Term Endothelin-A Receptor Antagonism Provides Robust Renal Protection in Humanized Sickle Cell Disease Mice.

  2017cites this paper
• Endothelin A receptor antagonists in diabetic kidney disease

  2017cites this paper
• Atrasentan for the treatment of diabetic nephropathy

  2017cites this paper
• MicroRNA-27a promotes podocyte injury via PPARγ-mediated β-catenin activation in diabetic nephropathy

  2017cites this paper
• Resistant Hypertension in Chronic Kidney Disease

  2017cites this paper
• ACE and SGLT2 inhibitors: the future for non‐diabetic and diabetic proteinuric renal disease

  2017cites this paper
• Integrating biomarkers to predict renal and cardiovascular drug efficacy

  2016cites this paper
• Global Overexpression of ET-1 Decreases Blood Pressure - A Systematic Review and Meta-Analysis of ET-1 Transgenic Mice

  2016cites this paper
• Conference on Endothelin Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

  2016cites this paper
• The heart as an extravascular target of endothelin-1 in particulate matter-induced cardiac dysfunction.

  2016cites this paper
• The Journal of Clinical Investigation

  2016cites this paper
• Diabetic Nephropathy: Focus on Current and Future Therapeutic Strategies.

  2016cites this paper
• Use of Multiple Biomarkers to Estimate Cardiovascular Drug Efficacy: Advantage of a PRE Score

  2016cites this paper
• Endothelin

  2016cites this paper
• Role of the endothelin system in sexual dimorphism in cardiovascular and renal diseases.

  2016cites this paper
• Dual inhibition of renin-angiotensin-aldosterone system and endothelin-1 in treatment of chronic kidney disease

  2016cites this paper
• Established and Emerging Strategies in the Treatment of Chronic Kidney Disease.

  2016cites this paper
• Mechanistic insight of diabetic nephropathy and its pharmacotherapeutic targets: An update.

  2016cites this paper